Board of Directors

Fernand Gagnon, Eng.
Fernand Gagnon is Co-founder of several companies and has 34 years of experience in: Business Development, Foreign Investment and Project Management with the Region of Montréal (Montréal Urban community); in Marketing and Product Development with Bell Canada, and in Engineering with Nortel Network.

Anatoly Langer, MD, MSc, FRCPC, FACC
Dr. Anatoly Langer graduated from the University of Manitoba in 1982 and completed his Internal Medicine and Cardiology training at the University of Toronto in 1987. He is a fellow of the American College of Cardiology and Canadian Royal College of Physicians and Surgeons. After two years as a Heart and Stroke Foundation Research Fellow he became a director of the Coronary Care Unit at St. Michael’s Hospital in Toronto, Canada. In 1996 Dr. Langer founded the Canadian Heart Research Centre with the goal of improving the care of cardiovascular patients through clinical trials research and education.

Dr. Langer has over 200 peer reviewed publications, abstracts and book chapters. His areas of interest and research include pathophysiology and the management of acute and stable coronary syndromes as well as the treatment and prevention of cardiovascular disease.

Currently Dr. Langer is a Professor of Medicine at the University of Toronto and a staff cardiologist at St Michael’s Hospital. He is Chair of the Canadian Heart Research Centre in Toronto. Dr. Langer has extensive research experience in the conduct of clinical trials with over 15 years of experience in protocol design, study coordination and data management.

Michael Moniz
A veteran of the private equity, investment banking and technology industries, Mr. Michael Moniz brings a unique perspective to developing companies in an executive, management and advisory capacity. He is the co-founder, President, and CEO of Circadence Corporation, a leader in the network optimization and cyber-defense markets. He is also a founding Managing Director with Paladin Capital Group, a leading multi-stage private equity firm. He serves as a founding Managing Director with Sage Canyon Advisors, a middle market investment bank focused on providing merger and acquisition advisory services for corporate and privately-held companies and holds Series 7, 62 and 24 licenses. Mr. Moniz sits on several corporate and non-profit boards including the ATLAS Institute at the University of Colorado. Mr. Moniz has been a two-time finalist for Ernst and Young’s prestigious Entrepreneur of the Year Award, and he is featured in the New York Times best-selling book How to Act Like a CEO by Debra Benton. He is an avid alpinist and in 2010, National Geographic named him one of their Ultimate Adventurers.

Martine A. Rothblatt, Ph.D., J.D., M.B.A.

Dr. Rothblatt founded United Therapeutics in 1996 and has served as Chairman and Chief Executive Officer since its inception. In 2004 she became CEO of Unither Biotech, Inc., a Quebec biotechnology company focused on developing and marketing life-saving treatments for pulmonary arterial hypertension. Prior to United Therapeutics, she founded and served as Chairman and Chief Executive Officer of Sirius Satellite Radio. She also represented the radio astronomy interests of the National Academy of Sciences’ Committee on Radio Frequencies before the Federal Communications Commission and led the International Bar Association’s efforts to present the United Nations with a draft Human Genome Treaty. Her book, YOUR LIFE OR MINE: HOW GEOETHICS CAN RESOLVE THE CONFLICT BETWEEN PUBLIC AND PRIVATE INTERESTS IN XENOTRANSPLANTATION, was published by Ashgate in 2004. She is the inventor on 3 patents for pulmonary hypertension treatments and one patent for satellite radio. She has served as a United Therapeutics director since 1996.

Employee Director

Duncan J. Stewart, MD

Executive Officers

Duncan J. Stewart, MD, President
Dr. Stewart received an MD from McGill University in 1977, where he also performed residency training in Internal Medicine and Cardiology.  He completed three years of research fellowship training in Physiology and Pharmacology in Freiburg, Germany.  He returned to Canada in 1987 as an Assistant Professor of Medicine at McGill University and staff cardiologist at the Royal Victoria Hospital and established a Vascular Biology Laboratory with a major interest in endothelial factors, in particular the role of nitric oxide and endothelin in the pathogenesis of vascular disease.  In 1994, he moved to Toronto and assumed the position of Head of Cardiology at St. Michael’s Hospital which he held until 2003.  In 1997, he became the Director of Cardiology of the University of Toronto and was awarded the Dexter Man Chair of Cardiology and in 1999.  He was promoted to Full Professor of Medicine at the University of Toronto in 1999, and in 2003 he became the Associate Director of Research at St. Michael’s Hospital.  In 2003 he was appointed as the leader of the Regenerative Medicine Program of the newly established McLaughlin Centre for Molecular Medicine, and in 2005 he assumed the Directorship of this Centre. In 2007, he was appointed CEO and Scientific Director of the Ottawa Hospital Research Institute and VP of Research for The Ottawa Hospital.

David W. Courtman, PH.D., Chief Scientific Officer
Dr. Courtman trained in Medical Biophysics at the University of Western Ontario receiving an Honours BSc and MSc. He then joined the vascular research program at the Toronto General Hospital earning a PhD in Cellular and Molecular Pathology from the University of Toronto in 1994. In his Post-Doctoral training at the University of Washington in Seattle he furthered his training in cardiovascular pathology under the mentorship of Dr. Stephen Schwartz and participated in the development of novel protein therapeutics through collaborations with scientists at ZymmoGenetics. In 1997 he took up a faculty position in the Department of Surgery at the University of Toronto and in 2008 became a scientist at the Ottawa Hospital Research Institute with a faculty position at the University of Ottawa. Dr. Courtman’s research has focused on the pathogenesis of the vascular system and the development of biomaterials and tissue engineered constructs to repair cardiovascular disorders. More recently he has concentrated on the enhancement of stem and progenitor cells for regeneration of chronic debilitating diseases that involve loss of vascular function.

Vatché Tchakmakian, C.A., Secretary-Treasurer
Mr. Tchakmakian is a chartered accountant specialized in the field of public companies and securities regulations in Canada. He served or currently serves as Chief Financial Officer for several emergent companies in the biotech and mining sectors. From 1988 to 1993, he managed audit assignments at a national accounting firm for a number of large private and public companies. Mr. Tchakmakian received his B.S. in Public Accounting from École des Hautes Études Commerciales, Université de Montréal in 1998.